International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
Bernhard Nocht Institute for Tropical Medicine The following list contains a few of the contributions made at the Bernhard Nocht Institute: Today the institute continues its research and treatment of tropical diseases, including dangerous diseases such as Lassa fever, Marburg virus, Ebola fever and leishmaniasis. Fleischer B. The Bernhard Nocht Institute: 100 years of tropical medicine in Hamburg. Mem Inst Oswaldo Cruz. 2000;95 Suppl 1:17-23. Bernhard Nocht Institute for Tropical Medicine Bernhard Nocht Institute for Tropical Medicine; (Bernhard-Nocht-Institut für Tropenmedizin) (BNI) is a medical institution based in Hamburg, Germany which is dedicated to research, treatment, training and therapy of tropical and infectious diseases. The body responsible